CLINUVEL PHARMACEUTICALS LIMITED (CUV)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
CUV - CLINUVEL PHARMACEUTICALS LIMITED
FNArena Sector :
Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Index: ASX200 | ASX300 | ALL-ORDS
FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
Clinuvel is a biopharmaceutical company that develops and commercialises treatments for patients with genetic, metabolic and life threatening disorders. The company was founded and listed in 2001.
| LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
|---|---|---|---|
|
$43.26
24 Sep |
OPEN $43.10 |
HIGH $44.67 |
205,640 LOW $42.57 |
-0.320| OTHER COMPANIES IN THE SAME SECTOR | |||
| ACR . AHZ . CSL . IDT . IVX . MSB . MYX . RNO . OSL . TFC . TIS . KZA . AGH . FTT . PAR . ADO . PYC . RAC . RCE . ZNO . AVH . LGP . SPL . ARX . AFP . 1AD . TLX . PNV . MVP . BNO . NXS . GSS . EOF . NEU . PAL . PBP . BOT . IMU . MDC . IMM . PXS . OPT . ANP . | |||
FNARENA'S MARKET CONSENSUS FORECASTS
- No Record -
Last ex-div: 02/09 - 2.5c (0%)
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2021 FactSet UK Limited. All rights reserved
| Title | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| EPS Basic | xxx | xxx | xxx | xxx | xxx | 50.1 |
| DPS All | xxx | xxx | xxx | xxx | xxx | 2.5 |
| Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 48.0 M |
| Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 199.8 |
| Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | 19.3 M |
| Net Profit Margin | xxx | xxx | xxx | xxx | xxx | 51.54 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
| Title | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Return on Assets | xxx | xxx | xxx | xxx | xxx | 26.01 % |
| Return on Equity | xxx | xxx | xxx | xxx | xxx | 28.69 % |
| Return on Total Capital | xxx | xxx | xxx | xxx | xxx | 30.50 % |
| Capex | xxx | xxx | xxx | xxx | xxx | 0.9 M |
| Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 1.78 % |
| Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | 17.2 M |
Return on Assets
Return on Equity
Return on Total Capital
Capex
Capex % of Sales
Free Cash Flow ex dividends
This is work in progress. Bear with us. It'll be amazing.
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
CUV STOCK CHART
FNArena News on CUV
| 1 |
August In Review: Eleventh Month Of GainsSep 10 2021 - Australia |
| 2 |
Rudi’s View: Investment Themes For The Year AheadSep 09 2021 - Rudi's View |
| 3 |
Australian Broker Call *Extra* Edition – Aug 09, 2021Aug 09 2021 - Daily Market Reports |
| 4 |
Australian Broker Call *Extra* Edition – Jun 18, 2021Jun 18 2021 - Daily Market Reports |
| 5 |
Australian Broker Call *Extra* Edition – May 26, 2021May 26 2021 - Daily Market Reports |
Latest Pharmaceuticals & Biotech/Lifesciences News
| 1 |
Beating The Biotech BluesSep 14 2021 - International |
| 2 |
Uncertainty Prevails For CSLAug 19 2021 - Australia |
| 3 |
Flying High – Medicinal Marijuana In AustraliaJul 26 2021 - Australia |
| 4 |
Wesfarmers On Drugs?Jul 13 2021 - Australia |
| 5 |
Is CSL’s Plasma Recovery Now Priced In?Jun 23 2021 - Australia |
| 6 |
CSL: Buy The DipJun 22 2021 - Technicals |
| 7 |
CSL To Retest Its High?May 25 2021 - Technicals |
| 8 |
Treasure Chest: CSL Plasma At Turning Point?May 05 2021 - Treasure Chest |
| 9 |
The War For DrugsApr 07 2021 - Weekly Reports |
| 10 |
Rudi’s View: CSL, The AnswersApr 01 2021 - Rudi's View |